AllPennyStocks.com IBRX Stock Gains As Soon-Shiong’s Nant Capital Backs Second Cancer-Immunotherapy Bet
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

IBRX Stock Gains As Soon-Shiong’s Nant Capital Backs Second Cancer-Immunotherapy Bet

PDS Biotech said it completed the initial close of a Nant Capital-led PIPE of up to $22.3 million and seated Soon-Shiong on its board — tying IBRX’s public face to a second immunotherapy platform.

Other Penny Stock Movers

This Critical Minerals Explorer Just Found Where to Look Next
Maiden Drill Campaign at Onuki Zone Concludes Under Sumitomo Earn-In
High-Grade 190 g/t Gold Grab Sample Highlights Manitoba Quartz Vein Expansion
Most Popular
{{ index + 1 }}
AllPennyStocks.com Favorites


Back to Top